An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily [BID]) in subjects with schizophrenia.

Study Overview

• Status: Enrolling by invitation
• Conditions: Schizophrenia
• Intervention / Treatment: Drug: Xanomeline and Trospium Chloride Capsules

• Study Type: Interventional
• Enrollment (Estimated): 280
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Megan Leader; Phone Number: +1 (857) 449-1020; Email: medinfo@karunatx.com

Study Locations

• Bulgaria
  • Kazanlak, Bulgaria, 6100
    • Clinical Trial Site
  • Sofia, Bulgaria, 1113
    • Clinical Trial Site
  • Varna, Bulgaria, 9020
    • Clinical Trial Site
• Serbia
  • Kragujevac, Serbia, 34000
    • Clinical Trial Site
• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72211
      • Clinical Trial Site
  • California
    • Bellflower, California, United States, 90706
      • Clinical Trial Site
    • Cerritos, California, United States, 90703
      • Clinical Trial Site
    • Garden Grove, California, United States, 92845
      • Clinical Trial Site
    • Lafayette, California, United States, 94549
      • Clinical Trial Site
    • Lemon Grove, California, United States, 91945
      • Clinical Trial Site
    • Torrance, California, United States, 90504
      • Clinical Trial Site
  • Florida
    • Hialeah, Florida, United States, 33016
      • Clinical Trial Site
    • Miami Lakes, Florida, United States, 33016
      • Clinical Trial Site
    • Tamarac, Florida, United States, 33319
      • Clinical Trial Site
  • Georgia
    • Atlanta, Georgia, United States, 30328
      • Clinical Trial Site
    • Decatur, Georgia, United States, 30030
      • Clinical Trial Site
  • Illinois
    • Chicago, Illinois, United States, 60640
      • Clinical Trial Site
  • Missouri
    • Saint Louis, Missouri, United States, 63128
      • Clinical Trial Site
  • Nevada
    • Las Vegas, Nevada, United States, 89102
      • Clinical Trial Site
  • New York
    • New York, New York, United States, 10017
      • Clinical Trial Site
    • Staten Island, New York, United States, 10314
      • Clinical Trial Site
  • Texas
    • Austin, Texas, United States, 78754
      • Clinical Trial Site
    • Irving, Texas, United States, 75062
      • Clinical Trial Site
  • Washington
    • Bellevue, Washington, United States, 98007
      • Clinical Trial Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subject is aged ≥18 to <60 years at the time of randomization of Study KAR-012
2. Subject has successfully completed the treatment period of Study KAR-012
3. Subject has been compliant with the procedures in Study KAR-012 (in the Investigator's judgement)
4. Subject has been compliant with their background antipsychotic drug in Study KAR-012 in the opinion of the Investigator and based on subject and informant reporting Note: Subjects are required to remain on the same appropriate approved APD as in Study KAR-012 and should stay on that same dose throughout the study.
5. Subject is capable of providing signed Informed Consent Form before any study assessments will be performed
6. Subject resides in a stable living situation, in the opinion of the Investigator
7. Subject has identified a reliable informant/caregiver willing and able to assist with study activities as needed throughout the subject's participation in the study. The informant can complete the study visits assessments via phone (as per local regulations). In Bulgaria, the informant needs to be physically present at all study visits where the Investigator determines that his/her input would be beneficial.
8. Women of childbearing potential (WOCP), or men whose sexual partners are WOCP, must be able and willing to use at least 1 highly effective method of contraception during the study and for at least 1 menstrual cycle (e.g., 30 days) after the last dose of study drug. Sperm donation is not allowed for 30 days after the final dose of the study drug. A female subject is considered to be a WOCP after menarche and until she is in a postmenopausal state for 12 months or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).

Exclusion Criteria:

1. Risk for suicidal behavior during the study as determined by the Investigator's clinical assessment and/or Columbia-Suicide Severity Rating Scale (C-SSRS) as confirmed by the following:

   1. Subject answers "Yes" to "suicidal ideation" Item 4 (active suicidal ideation with some intent to act, without a specific plan) or Item 5 (active suicidal ideation with a specific plan and intent) on the C-SSRS
   2. Non-suicidal self-injurious behavior is not exclusionary
2. Any clinically significant abnormalities, including any finding(s) from ECG, or laboratory test at Visit 6, and the physical examination, vital signs, at the EOT visit of Study KAR-012 that the Investigator, in consultation with the Medical Monitor are considered to jeopardize the safety of the subject
3. Female subject is pregnant
4. If, in the opinion of the Investigator (and/or Sponsor/ Medical Monitor), subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the Investigator (and/or Sponsor /Medical Monitor), may compromise the safety of the subject or affect their ability to adhere to the protocol visit schedule or study requirements
5. Risk of violent or destructive behavior as per Investigator's judgement
6. Subjects participating in another investigational drug or device trial or planning on participating in another clinical trial during the study
7. History or high risk of urinary retention, gastric retention, or narrow angle glaucoma as evaluated by the Investigator
8. Subject is taking, or plans to take while in the study, any prohibited concomitant medication

9. For all male subjects only, any one of the following:

   1. History of bladder stones
   2. History of recurrent urinary tract infections
   3. Serum prostate specific antigen (PSA) >10 ng/mL
   4. An International Prostate Symptom Score (IPSS) of 5 (almost always) on either item 1, 3, 5, or 6
   5. A sum of scores on IPSS items 1, 3, 5, and 6 of ≥9 Note: IPSS will be required only for male subjects ≥ 45 years of age. Subjects already enrolled in the study who do not have available PSA values from Study KAR-012 for baseline value use in Study KAR-013, will have these assessments at their next clinic visit planned after re-consenting to determine current eligibility.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Drug: KarXT	Drug: Xanomeline and Trospium Chloride Capsules; KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of treatment-emergent adverse events (TEAEs)	From initial dose to safety follow-up visit (54 weeks) or early termination

Secondary Outcome Measures

Outcome Measure	Time Frame
Incidence of serious treatment-emergent adverse events (TEAEs)	From initial dose to safety follow-up visit (54 weeks) or early termination
Incidence of TEAEs leading to discontinuation of study drug	From initial dose to safety follow-up visit (54 weeks) or early termination

Collaborators and Investigators

• Sponsor: Karuna Therapeutics
• Investigators: Study Director: Inder Kaul, MD, Karuna Therapeutics

Study record dates

Study Major Dates

• Study Start (Actual): March 7, 2022
• Primary Completion (Estimated): February 1, 2026
• Study Completion (Estimated): February 1, 2026

Study Registration Dates

• First Submitted: March 21, 2022
• First Submitted That Met QC Criteria: March 30, 2022
• First Posted (Actual): March 31, 2022

Study Record Updates

• Last Update Posted (Actual): March 22, 2024
• Last Update Submitted That Met QC Criteria: March 20, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Parasympatholytics; Autonomic Agents; Peripheral Nervous System Agents; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Urological Agents; Psychotropic Drugs; Cholinergic Agonists; Parasympathomimetics; Muscarinic Agonists; Trospium chloride; Xanomeline
• Other Study ID Numbers: KAR-013

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No